Grin Therapeutics
Grin Therapeutics raises $140M Series D at $700M valuation
Grin Therapeutics: Series D Funding Round
Grin Therapeutics has successfully raised $140M in Series D funding, reaching a valuation of $700M.
Company Overview
Developer of therapies treating serious neurodevelopmental disorders
Funding Details
The Series D round was led by Fidelity, with participation from Viking Global.
Company Information
- Headquarters: New York, NY
- Founded: 2018
- Employees: 90+
- Category: Biotech
Investment
Grin Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Fidelity: Verified investor in Series D
- Viking Global: Verified investor in Series D
Company Info
Investors (2)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free